Federated Hermes’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2
| Closed | -$19 | – | 2196 |
|
|
2025
Q2 | $19 | Hold |
2
| – | – | ﹤0.01% | 2052 |
|
|
2025
Q1 | $15 | Sell |
2
-2
| -50% | -$15 | ﹤0.01% | 2045 |
|
|
2024
Q4 | $34 | Buy |
4
+1
| +33% | +$10 | ﹤0.01% | 2057 |
|
|
2024
Q3 | $26 | Buy |
3
+2
| +200% | +$16 | ﹤0.01% | 2035 |
|
|
2024
Q2 | $7 | Sell |
1
-59
| -98% | -$364 | ﹤0.01% | 2009 |
|
|
2024
Q1 | $546 | Buy |
+60
| New | +$426 | ﹤0.01% | 1984 |
|
|
2023
Q3 | – | Sell |
-2,747
| Closed | -$14.2K | – | 2168 |
|
|
2023
Q2 | $14.2K | Buy |
2,747
+2,527
| +1,149% | +$15K | ﹤0.01% | 1817 |
|
|
2023
Q1 | $1.16K | Sell |
220
-141
| -39% | -$670 | ﹤0.01% | 2036 |
|
|
2022
Q4 | $1.01K | Sell |
361
-801,375
| -100% | -$2.65M | ﹤0.01% | 2054 |
|
|
2022
Q3 | $3.33M | Sell |
801,736
-390,336
| -33% | -$1.97M | 0.01% | 765 |
|
|
2022
Q2 | $4.79M | Buy |
1,192,072
+569,792
| +92% | +$2.15M | 0.01% | 691 |
|
|
2022
Q1 | $3.08M | Buy |
+622,280
| New | +$3.45M | 0.01% | 904 |
|
|
2021
Q2 | – | Sell |
-313,238
| Closed | -$5.14M | – | 2292 |
|
|
2021
Q1 | $5.14M | Buy |
313,238
+64,327
| +26% | +$1.24M | 0.01% | 847 |
|
|
2020
Q4 | $5.15M | Buy |
248,911
+248,702
| +118,996% | +$3.69M | 0.01% | 800 |
|
|
2020
Q3 | $2K | Buy |
+209
| New | +$1.74K | ﹤0.01% | 2101 |
|
|
2018
Q2 | – | Sell |
-11
| Closed | -$1K | – | 2262 |
|
|
2018
Q1 | $1K | Sell |
11
-110
| -91% | -$619 | ﹤0.01% | 2112 |
|
|
2017
Q4 | $1K | Hold |
121
| – | – | ﹤0.01% | 2123 |
|
|
2017
Q3 | $1K | Sell |
121
-143
| -54% | -$921 | ﹤0.01% | 2097 |
|
|
2017
Q2 | $2K | Buy |
+264
| New | +$2.56K | ﹤0.01% | 2046 |
|
|
2016
Q4 | – | Sell |
-261,700
| Closed | -$1.8M | – | 2152 |
|
|
2016
Q3 | $1.8M | Sell |
261,700
-1,134,587
| -81% | -$6.92M | 0.01% | 893 |
|
|
2016
Q2 | $6.91M | Sell |
1,396,287
-250,946
| -15% | -$2.49M | 0.02% | 478 |
|
|
2016
Q1 | $15.9M | Hold |
1,647,233
| – | – | 0.05% | 312 |
|
|
2015
Q4 | $15.4M | Sell |
1,647,233
-71,247
| -4% | -$769K | 0.05% | 333 |
|
|
2015
Q3 | $24.2M | Buy |
1,718,480
+358,780
| +26% | +$7.21M | 0.08% | 252 |
|
|
2015
Q2 | $28.6M | Buy |
1,359,700
+1,131,900
| +497% | +$28M | 0.09% | 249 |
|
|
2015
Q1 | $9.56M | Sell |
227,800
-122,200
| -35% | -$4.02M | 0.03% | 469 |
|
|
2014
Q4 | $8.23M | Hold |
350,000
| – | – | 0.03% | 493 |
|
|
2014
Q3 | $5.24M | Buy |
+350,000
| New | +$5.18M | 0.02% | 625 |
|
Other funds holding OCUL
VA
SR
DTC
ACA
TCM
Federated Hermes's OCUL Position: Q3 2025 in Review
Federated Hermes sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 2 shares — an estimated $19 sold.
Federated Hermes first reported a position in OCUL in Q3 2014 and held it in 28 quarters. The position peaked at $28.6M in Q2 2015. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.
- Federated Hermes reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
- Federated Hermes sold 2 Ocular Therapeutix shares in Q3 2025, an estimated $19.
- Federated Hermes first reported a position in Ocular Therapeutix in Q3 2014 and held it in 28 quarters.
- Federated Hermes's Ocular Therapeutix position peaked at $28.6M in Q2 2015.
- 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.
Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.